Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Tigecycline Recombinant Mouse Monoclonal Antibody (1B9)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Tigecycline Antibody (MA566278) in SDS-PAGE
SDS-PAGE characterization of Tigecycline under reducing conditions. Lane M: Protein marker (kDa); Lane TGC: Purified Tigecycline Recombinant Monoclonal (Product # MA566278). Tigecycline showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-421.
产品信息
MA566278
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
1B9
抗原
Conjugate of TGC hapten and KLH.
偶联物
形式
Liquid
浓度
1.6 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Tigecycline is a semisynthetic antibiotic belonging to the glycylcycline class, developed to treat polymicrobial infections caused by multidrug-resistant Gram-positive and Gram-negative pathogens. It is designed to evade tetracycline resistance mechanisms, such as ribosomal protection and active drug efflux. Tigecycline functions by binding to the 30S ribosomal subunit, inhibiting protein synthesis in bacteria, which makes it effective against a wide range of bacterial infections. Despite its efficacy, the emergence of high-level tigecycline resistance, particularly mediated by plasmid-encoded genes like tet(X), poses a significant challenge to its clinical use. Strategies to overcome resistance include combining tigecycline with adjuvants like curcumin, which can reverse resistance mechanisms. Tigecycline is administered intravenously and is considered a last-resort antibiotic due to its broad-spectrum activity and ability to overcome resistance mechanisms.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
